This is the first gene editor to use a CRISPR-associated transposase to make targeted edits at therapeutically useful levels in humans.

Element has responded to the lawsuit with a statement saying, “Element is proud of its strong history of innovation. We are reviewing the complaint and look forward to defending our innovations in ...

BioMarin agreed to shell out approximately $270 million for Inozyme Pharma, a developer whose treatments target the PPi-adenosine pathway, a key regulator of bone health and blood vessel function.

Scientists say study findings indicate that TC IV cells may represent a therapeutic target for the treatment of ...

Estrogen-related receptors (ERRs) regulate muscle mitochondria in mice, revealing a new potential drug targets for metabolic ...

Researchers were able to test how viruses replicate differently across various bat species and organs using the new organoid ...

How malaria parasites exploit mechanism for escaping elimination could provide novel strategies targeting chronic malaria ...

Treated with an individualized gene-editing therapy that corrects mutations directly on the genome, a patient shows ...

CEO Serge Saxonov, PhD, acknowledged that its R&D operation “definitely ended up being impacted in a substantial way” while ...

Imprint has raised $15 million to decode the body's immune memory for understanding chronic diseases, such as long-COVID and ...

Current setbacks cannot prevent gene-editing companies from advancing closer to “one-and-done” cures and new products.

To address this challenge, CTMC has established a patient material bank, enabling early-stage process development with clinically relevant samples. This resource also supports continuous process ...